Add BrightSurf on Google Email

A patch of protection against Zika virus

A new vaccine patch has delivered an effective immune response to Zika virus in mice, providing rapid protection against the disease. The patch, which uses a high-density microarray platform, targets a specific protein crucial to the virus's survival and evokes T-cell responses up to 270% higher than traditional vaccines.

SourceUniversity of Queensland·JournalMolecular Therapy — Nucleic Acids·DateNov 30, 2023

Research shows infants exposed to certain biologics during pregnancy can safely receive rotavirus vaccine

A Canadian study found that infants exposed to biologic agents during pregnancy have normal immune development and can safely receive the rotavirus vaccine. The study, involving 191 infants across six sites in Canada, aimed to change vaccination guidelines to protect more babies from severe illness.

SourceUniversity of Calgary·JournalThe Lancet Child & Adolescent Health·TypeObservational study·DateNov 23, 2023

NUS Medicine researchers unlock the potential of genetic glycoengineering to advance vaccines and therapeutics technology

The team created a glycoengineering platform that simplifies the production of customized sugar carbohydrates, known as glycans, which play a crucial role in various therapeutic applications. This innovation enables the engineering of new glycans with unprecedented flexibility, addressing limitations in existing approaches.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalScience Advances·TypeRandomized controlled/clinical trial·DateOct 16, 2023

Elderly patients receiving high-quality primary care are more likely to receive varicella-zoster virus vaccination on doctor's recommendation

A study by University of Tsukuba found that elderly patients receiving better services from their primary care providers are more likely to receive the varicella-zoster virus vaccination. The study suggests that providing adequate services needed by patients during primary care may improve shingles vaccine coverage.

SourceUniversity of Tsukuba·JournalJournal of Primary Care & Community Health·DateSep 22, 2023

Leading the way in global STI research

A new study published in Virology Journal confirms 25 different types of HPV prevalent in Nigeria, highlighting the need for region-specific vaccines. The discovery underscores the limitations of existing vaccines like Gardasil-9, which only protects against nine cancer-causing types.

SourceUniversity of Delaware·JournalVirology Journal·DateSep 19, 2023

Community health program boosts child vaccinations in remote areas of Madagascar

A community-based health program implemented in Madagascar increased vaccination rates in the country's most remote villages. The study found that households with a Catholic or Protestant affiliation were more reluctant to vaccinate their children, highlighting the need to address these barriers in future programs.

SourceUniversity of Illinois College of Agricultural, Consumer and Environmental Sciences·JournalWorld Development·TypeData/statistical analysis·DateAug 10, 2023

How to increase acceptance of an RSV vaccine? Explain the FDA’s vaccine approval process

A new study by the Annenberg Public Policy Center found that people are more likely to recommend an RSV vaccine if they understand the rigorous process of the FDA's vaccine approval process. The study showed that 57% of those exposed to a flowchart were very or somewhat likely to recommend the vaccine, compared to 40% in a control group.

Family medicine physicians receive lowest HPV vaccine cost reimbursements compared to pediatricians, internal medicine doctors, nurse practitioners and other specialists

A study found that family medicine physicians have the lowest net returns per dose for HPV vaccines, while pediatricians received higher reimbursement amounts. The researchers also observed a positive association between reimbursement and increased HPV vaccine doses administered, particularly among family physicians.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateJul 25, 2023

THE LANCET: First phase 3 trial of a chikungunya vaccine candidate finds it is generally safe and provokes an immune response

A phase 3 trial found that the VLA1553 vaccine candidate produced an immune response in 99% of participants, inducing protection against disease. The study also showed that the vaccine was generally safe and well-tolerated across all age groups, with most adverse events being mild or moderate.

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJun 12, 2023

Personalized vaccines may revolutionize cancer treatment

Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.

SourceEdith Cowan University·TypeRandomized controlled/clinical trial·DateJun 8, 2023

Study investigates how the severity of effects of the SARS-CoV-2 virus in England was affected by the mass vaccination campaign and emergence of Alpha, Delta and Omicron variants between May 2020 and March 2022

Researchers analyzed hospitalization and fatality rates of SARS-CoV-2 infection in England between May 2020 and March 2022. The study found that the mass vaccination campaign significantly reduced severe effects of the virus, with notable improvements after the emergence of Alpha, Delta, and Omicron variants.

SourcePLOS·JournalPLOS Biology·DateMay 25, 2023

LSU Health New Orleans study finds diet contributes to risk of HPV-related cancer

A new study published by LSU Health New Orleans found that a diet high in fruits, dark-green vegetables, and beans can significantly lower the risk of genital high-risk-HPV infection, which is associated with cervical cancer. The research also showed that women who eat healthily tend to practice other healthy behaviors.

SourceLouisiana State University Health Sciences Center·JournalThe Journal of Infectious Diseases·TypeData/statistical analysis·DateMay 25, 2023

NUS researchers uncover new differences in bacteria’s sugar coat to aid pneumococcal vaccine development

Researchers from NUS Medicine discovered that specific CPS structures and sugar combinations help Streptococcus pneumoniae colonize the human respiratory tract. The study sheds light on the importance of CPS structure in bacterial survival, which will inform future vaccine development.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalProceedings of the National Academy of Sciences·TypeRandomized controlled/clinical trial·DateApr 17, 2023

Vaccination against chickenpox is estimated to significantly reduce varicella cases and deaths in both children and adults and would be cost-effective, per a modelling study in Denmark, informing policymakers around routine immunization

A modelling study in Denmark found that universal varicella vaccination significantly reduces chickenpox-related cases and deaths in both children and adults. The study also showed cost-effectiveness of the vaccine, informing policymakers about routine immunization.

SourcePLOS·JournalPLOS Global Public Health·DateApr 5, 2023

A 21st-century remedy for missed meds

Researchers at Rice University have created a new technology called PULSED that can deliver time-released drugs and vaccines for extended periods. The technology uses high-resolution 3D printing and soft lithography to produce microcylinders made of biodegradable polymers, which can be loaded with drugs and release them over time.

SourceRice University·JournalAdvanced Materials·TypeExperimental study·DateApr 3, 2023

Immune Development in Early Life (IDEAL) study to identify new approaches for predicting and preventing childhood disease

An international project aims to discover modifiable cellular and molecular pathways of the developing infant immune system to improve infant vaccine responsiveness and prevent respiratory disease. By analyzing infants' immune systems from birth to five years old, researchers hope to identify biomarkers that predict vaccine responsiven...

Making immunizations more effective

Researchers have created two novel adjuvants that significantly enhance the immune response to vaccines. The new adjuvants target toll-like receptors and are designed to be tailored for every individual vaccine, potentially reducing side effects and increasing effectiveness.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateMar 27, 2023